Abstract The aim of the present work was to clarify the anti-melanogenic mechanism of non-steroidal anti-inflammatory drugs (NSAIDs). Mefenamic acid, diclofenac, and nimesulide were used in this study, and these drugs inhibit melanin synthesis in B16F1 melanoma cells. To elucidate the anti-melanogenic mechanism of NSAIDs, we performed western blotting analysis for melanogenic proteins, such as tyrosinase, TRP-1, and TRP-2. All NSAIDs used in this study inhibited tyrosinase protein level. Semi-quantitative RT-PCR analysis showed that the depigmentation effect of mefenamic acid and nimesulide might be due to the inhibition of tyrosinase gene transcription. These results indicate that NSAIDs inhibit a-MSH-enhanced melanin synthesis, and are candidate anti-melanogenic agents since they might be effective in hyperpigmentation disorders.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to act by directly suppressing the activity of cyclooxygenase (COX), the key enzyme catalyzing the biosynthesis of prostaglandins, which induce inflammation. Therefore, NSAIDs are generally used to treat pain, inflammation, and fever. NSAIDs are able to prevent the development of cancer of the colon, breast, stomach, and lung [9, 18, 19, 32] . These biological effects of NSAIDs are the result of their ability to induce apoptosis and cell cycle arrest [11, 17] . Acetylsalicylic acid is one of the most well-studied NSAIDs, and has been shown to be effective as an antiplatelet drug in preventing heart attacks, stroke, and cerebral thrombosis [4, 6, 29] .
Human skin pigmentation is caused by melanin synthesis in UV irradiated melanocytes. Tyrosinase is a key enzyme in melanin synthesis, and can catalyze three different reactions: the hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA), the oxidation of DOPA to DOPAquinone, and the oxidation of 5,6-dihydroxyindole (DHI) to indole-quinone [8] . In the absence of thiols, DOPAquinone changes to DOPAchrome and then to DHI or indole 5,6-quinone 2-carboxylic acid (DHICA). There are two other main enzymes in this melanogenic pathway: tyrosinase-related protein-2 (TRP-2; DOPAchrome tautomerase), which catalyzes the conversion of DOPAchrome to DHICA, and TRP-1 (DHICA oxidase), which catalyzes the oxidation of DHICA [2, 10, 13, 14, 31] .
There are several signal pathways for enhancing melanin production. The cAMP-mediated pathway is a well-known melanin synthesis cascade. a-Melanocyte stimulating hormone (a-MSH), prostaglandin E 2 (PGE 2 ), and adrenocorticotropic hormone (ACTH) activate the cAMP-mediated pathway [5, 26, 27] . The cGMP-mediated pathway can also increase the melanin production. This pathway is activated by nitric oxide (NO), which is released by keratinocytes irradiated by UV-B [20] . In human melanocytes, Park et al. [16] reported that protein kinase C (PKC) can phosphorylate serine residues of tyrosinase at positions 505 and 509 in the cytoplasmic domain, and that this phosphorylation can enhance tyrosinase activity. UV light might affect cell membranes and activate phospholipase C, releasing diacylglycerol (DAG), which can activate PKC [21] . Microphthalmia-associated transcription factor (Mitf) has a crucial role in the transcription of melanogenic genes. Mitf is a transcription factor of the basic helix-loop-helix leucine zipper (bHLH-LZ) family, which binds a highly conserved motif termed the M-box to activate melanogenic gene transcription factors such as tyrosinase, TRP-1, and TRP-2. Mitf expression is regulated by several transcription factors.
Recently, we found that acetylsalicylic acid (aspirin) inhibits melanogenesis on B16 melanoma cells by downregulation of tyrosinase protein level [22] . However, studies on anti-melanogenic effects of other NSAIDs were not reported. Therefore, it is important to investigate the effect of other NSAIDs on melanogenesis. In the present study, we investigated the effects of NSAIDs on aspects of melanogenic-related gene transcription and protein expression.
Materials and methods

Cell culture
B16F1 murine melanoma cells were cultured in Dulbecco's modified eagle's medium (DMEM) (Sigma, St. Louis, MO, USA) supplemented with 5% heat-inactivated fetal bovine serum (FBS), 50 U/ml penicillin and 100 lg/ ml streptomycin at 37°C in a humidified atmosphere containing 5% CO 2 . For the cell proliferation assay, measurement of melanin content, DOPA staining, western blotting and reverse transcription-polymerase chain reaction (RT-PCR), the cells were sub-cultured in 60 mm culture dishes at a density of 1 9 10 5 cells/dish before treatment.
Cell proliferation
NSAIDs (mefenamic acid, diclofenac, and nimesulide) were purchased from Sigma (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO). NSAIDs were added to the cell cultures at final concentrations of 50 and 100 lM for 5 days, respectively. All culture dishes had a-MSH (Sigma) added to them at the final concentrations of 10 nM. Cells were collected with trypsin/ethylenediaminetetraacetic acid after treatment, and were counted with a Fuchs-Rosenthal cytometer.
Measurement of melanin content
Melanin content was measured as described previously [23] . The cells were treated with NSAIDs (50 and 100 lM) in the presence of a-MSH (10 nM) for 5 days. After treatment, the cells were detached by incubation in trypsin/ ethylenediaminetetraacetic acid. After precipitation, cell pellets (1 9 10 6 cells) were solubilized in 1 ml boiling 2 M NaOH for 20 min. Spectrophotometric analysis of melanin content was performed at 405 nm absorbance. We also observed melanoma under microscopy.
Tyrosinase assay
Tyrosinase assay was performed as reported by Masamoto et al. [15] with slight modifications. First, 300 ll of 2.5 mM 3,4-dihydroxyphenylalanine (L-DOPA) solution, 50 ll of DMSO with or without a sample chemical, and 1.1 ml of 0.1 M phosphate buffer (pH 6.8) were mixed. The mixture was preincubated at 25°C for 10 min before 50 ll of 1,380 units/ml tyrosinase in aqueous solution was added, and the reaction was monitored at 475 nm by a UV spectrophotometer. A control reaction was conducted with DMSO alone. The percentage of activity of tyrosinase was calculated as follows: 100-[(A-B)/A 9 100], where A represents the difference in the absorbance of the control sample between an incubation time of 0.5 and 1.0 min, and B represents the difference in the absorbance of the test sample over the same incubation period.
DOPA staining of gels
The DOPA staining assay was performed as described previously [24] . B16F1 melanoma cells, which were stimulated by a-MSH (10 nM), were treated with or without NSAIDs (50 and 100 lM) for 5 days. To identify the active form of tyrosinase, samples lysed in 0.1 M sodium phosphate buffer (pH 6.8) containing 1% Triton X-100, 1 mM PMSF(phenylmethylsulfonyl fluoride), 10 lg/ ml aprotinin, and 10 lg/ml leupeptin (but without mercaptoethanol or heating) were resolved by 7.5% SDSpolyacrylamide gel electrophoresis. Gels containing tyrosinase bands were placed in a flat-bottomed container with 200 ml of rinse buffer (0.1 M NaH 2 PO 4 , pH 6.8) and equilibrated at room temperature with gentle shaking. After 30 min, the rinse buffer was drained from the gels and replaced with fresh buffer. After repeating the rinse procedure once more, the gels were transferred into 200 ml of a staining solution that contained the rinse buffer supplemented with 5 mM L-DOPA, and incubated in a dark place for 3 h at 37°C. Protein bands that contained tyrosinase activity were visualized in the gels as dark bands.
Western blotting
To determine the amount of tyrosinase and tyrosinase-related protein expression, western blotting analysis was performed. B16F1 melanoma cells that had been stimulated by a-MSH were treated with NSAIDs (50-150 lM) for 3 or 5 days. After treatment, the cells were collected and lysed with cell lysis buffer [50 mM Tris-HCl (pH6.8), 2% SDS, 6% b-mercaptoethanol, 1% glycerol]. Whole cell lysates (5 9 10 4 Cells equivalents per lane) were separated by 7.5% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk in phosphate-buffered saline containing 0.05% Tween 20. Tyrosinase, TRP-1, and TRP-2 bands were detected with the rabbit polyclonal anti-tyrosinase antibody (dilution 1:1,000), rabbit polyclonal anti-TRP-1 antibody (dilution 1:1,000), and rabbit polyclonal anti-TRP-2 antibody (dilution 1:500), respectively, which were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and then further incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody at a 1:1,500 dilution. Bound antibodies were detected using an enhanced chemiluminescence kit (Amersham) following the manufacturer's instructions. Loading control was assessed using anti-b-actin antibody.
Semi-quantitative reverse transcription-polymerase chain reaction
To investigate the effect of NSAIDs on melanogenic gene expression, semi-quantitative RT-PCR analysis was performed. B16F1 melanoma cells were treated with or without NSAIDs (50 and 100 lM) and stimulated with a-MSH (10 nM) for 48 h, and we also performed the RT-PCR analysis using B16F1 melanoma without a-MSH stimulation.
After treatment, total RNA was extracted from the cells using ISOGEN (NIPPON GENE, Japan). Reverse transcription and cDNA amplification were carried out with 1 lg of isolated total RNA using the TaKaRa RT-PCR kit (TaKaRa). All procedures were conducted following the manufacturer's instructions.
The oligonucleotide primers used for the PCR were as follows: tyrosinase upstream 5 0 -TGT CCC AAG TAC AGG GAT CG-3 and 60 s at 72°C. After amplification, 50% of the reaction mixture was analyzed by electrophoresis on 1.5% agarose gels and stained with ethidium bromide. In order to check the reproducibility of the results, each experiment was carried out more than three times. Specific primers for GAPDH were used as controls.
Statistical analysis
All statistical calculations were carried out using the SPSS software (14.0 for windows) program. Data were analyzed using the Dunnett's test.
Results
The effect of NSAIDs on cell proliferation
To test the effect of NSAIDs on cell proliferation, B16F1 melanoma cells were incubated with mefenamic acid, diclofenac and nimesulide (50 or 100 lM) for 5 days. Melanoma cell numbers were decreased when stimulated with a-MSH (Fig. 1) . In a-MSH-stimulated melanoma cells, mefenamic acid enhanced the cell growth in a dosedependent manner (approximately 120% at 50 lM, 170% at 100 lM versus a-MSH alone treated cells) (Fig. 1 ). Diclofenac and nimesulide had no significant effect on cell proliferation.
Melanin formation
To determine the effects of NSAIDs on melanogenesis, B16F1 melanoma cells stimulated with a-MSH were cultured in the presence of mefenamic acid, diclofenac, and nimesulide at 50 or 100 lM for 5 days. The melanin content of the B16F1 melanoma cells that had not been treated with stimulants such as a-MSH was very low (Fig. 2a) . Melanin formation by B16F1 melanoma cells was significantly inhibited in the presence of mefenamic acid (approximately 46% at 50 lM and 22% at 100 lM) or with diclofenac treatment (approximately 61% at 50 lM and 22% at 100 lM). Nimesulide also inhibits melanogenesis at 100 lM treatment (37% of control). As shown in Fig. 2b , melanin formation in B16F1 melanoma was inhibited by NSAID treatment. 
Tyrosinase activity
We examined the inhibitory effect of NSAIDs (mefenamic acid and diclofenac) on tyrosinase using mushroom tyrosinase. As shown in Fig. 3 , mushroom tyrosinase activity was slightly inhibited when treated with either mefenamic acid (approximately 7 ± 4% at 100 lM and 13 ± 2% at 200 lM) or diclofenac (approximately 16 ± 7% at 200 lM). Nimesulide also inhibited tyrosinase activity at 100 lM (21 ± 4%), but at 200 lM, treatment had no significant inhibition (7 ± 1%). This inconsistency probably results from the yellow color of the nimesulide solution, so tyrosinase activity could not be measured precisely in our experimental conditions.
DOPA staining assay of NSAIDs treated cells
To investigate the mechanism of pigmentation inhibition by NSAIDs, we performed DOPA staining on SDS-PAGE gels (Fig. 4) . We can use this to estimate the amount of the active form of tyrosinase generated and removed by de novo synthesis and proteolysis, respectively, because DOPA staining directly detects the tyrosinase activity of protein bands. B16F1 melanoma cells were treated with either a-MSH alone or a-MSH plus one of the test substances (mefenamic acid, diclofenac, and nimesulide at 50 or 100 lM) for 5 days.
Cell lysates were applied to SDS-PAGE and the bands that retained tyrosinase activity were detected as described in ''Materials and methods''. The tyrosinase activity of B16F1 melanoma cells not stimulated by a-MSH was very low (Fig. 4) . In the treatments with a-MSH, tyrosinase activity increased dramatically. Moreover, mefenamic acid, diclofenac, and nimesulide inhibited a-MSH-enhanced tyrosinase activity in a dosedependent manner. These results corresponded with the result for the melanin content assays described in Fig. 2 .
Influence of NSAIDs on melanogenic protein expression
To investigate whether NSAIDs can influence melanogenic protein expression, western blotting analysis was carried out using the lysate of B16F1 melanoma cells treated with NSAIDs and stimulated by a-MSH (10 nM) for 5 days (Fig. 5a ). When the cells were treated with a-MSH, a significant increase in tyrosinase protein level was observed and TRP-1 expression also increased. All NSAIDs used in this study inhibited a-MSH-stimulated tyrosinase expression of B16F1 melanoma cells in a dose-dependent manner. Tyrosinase protein level was decreased by NSAIDs for 3-day treatment (Fig. 5b) . TRP-1 expression was slightly inhibited by diclofenac treatment. However, TRP-2 level showed no significant change.
Influence of NSAIDs on melanogenic gene transcription
To investigate the effects of NSAIDs on melanogenic gene transcription, semi-quantitative RT-PCR analysis was carried out. B16F1 melanoma cells were treated by NSAIDs for 48 h. As shown in Fig. 6a , tyrosinase mRNA level was increased by a-MSH stimulation. In treatment with mefenamic acid and nimesulide, a-MSHenhanced tyrosinase gene transcription was decreased.
On the other hand, diclofenac did not inhibit tyrosinase mRNA level. TRP-1, TRP-2, and Mitf gene expression were decreased in a-MSH-stimulated cells. However, NSAID-treated cells did not show significant change of TRP-1, TRP-2, and Mitf mRNA levels. In this study, we also investigated the influence of NSAIDs on melanogenic gene transcription of unstimulated cells. B16F1 melanoma cells were treated with mefenamic acid, diclofenac and nimesulide (50 or 100 lM) in the absence of a-MSH, and RT-PCR was performed (Fig. 6b) . In this experimental condition, melanogenic gene transcription was not affected by NSAIDs treatment. The gene expression level of GAPDH used as an internal control also showed no change during this experiment.
Discussion
In the present study, we have demonstrated the inhibitory mechanism of NSAIDs (using mefenamic acid, diclofenac and nimesulide as NSAIDs) in B16F1 melanoma cells. NSAIDs inhibited melanin production in a-MSH-stimulated melanoma cells. a-MSH acts on cells through the elevation of cAMP concentration resulting in the enhancement of melanin production. a-MSH binds to the melanocortin 1 receptor (MC1R) and activates adenylate cyclase, which increases the intracellular cAMP concentration [1] . cAMP activates protein kinase A (PKA), which subsequently phosphorylates cAMP response binding protein (CREB). CREB binds to the cAMP response element (CRE) motif of the Mitf promoter and activates Mitf gene transcription [26] . Mitf is a transcription factor that effectively transactivates the expression of tyrosinase and its related genes by binding to their common promoters [3] . NSAIDs significantly inhibited melanin synthesis in a-MSH-stimulated B16F1 melanoma cells. This result is not explained by the toxicity of NSAIDs because NSAIDs did not show any inhibitory effect on cell proliferation.
There are three well-known enzymes in melanin synthesis: tyrosinase, TRP-1, and TRP-2 [12] . Especially, tyrosinase has a crucial role of melanin synthesis. Therefore, to clarify the direct inhibitory effect of NSAIDs on mushroom tyrosinase, we performed a tyrosinase assay. In the tyrosinase assay, NSAIDs slightly inhibited mushroom tyrosinase activity. Diclofenac showed over 40% inhibition of tyrosinase activity at 2 mM (data not shown). At 100 lM, mefenamic acid and diclofenac inhibited mushroom tyrosinase activity by approximately 10%, and nimesulide inhibited it by 20%. On the other hand, melanoma cells were treated with NSAIDs at 100 or 200 lM in the melanin content assay. Therefore, the direct inhibitory effect of tyrosinase of these drugs does not greatly contribute to the anti-melanogenic effect on melanoma cells. NSAIDs for 48 h in the presence or absence of a-MSH. Mefenamic acid and nimesulide inhibited a-MSHenhanced tyrosinase mRNA level. However, diclofenac did not inhibit a-MSH-enhanced tyrosinase mRNA level. On the other hand, Mitf mRNA level was decreased by treatment of a-MSH. It is well-known that Mitf mRNA transcription is stimulated by cAMP inducers such as a-MSH and 3-isobutyl-1-methylxanthine (IBMX). However, the Mitf mRNA level reached maximum level at 80 min after a-MSH stimulation and decreased at 180 min after stimulation (data not shown). In the a-MSH-unstimulated melanoma cells, NSAIDs (mefenamic acid, diclofenac, and nimesulide) did not affect melanogenic gene transcription at 50 and 100 lM. These results show that NSAIDs do not influence TRP-1 and TRP-2 mRNA transcription.
Also the mRNA level of transcription factors such as Mitf was not inhibited. Mitf plays a crucial role in melanogenesis as the master regulator of tyrosinase, TRP-1 and TRP-2 gene transcription, and subsequently causes hypopigmentation. Therefore, mutation of Mitf can cause pigmentation disorders as observed in Waardenburg syndrome [7, 28, 30] . Moreover, other transcription factors mutations such as Pax3 and Sox10 cause this disease [25] . Previously, we reported that acetylsalicylic acid (aspirin) inhibits tyrosinase protein level on B16F1 melanoma cells [22] . We also performed an RT-PCR assay on aspirintreated cells. In the result of this experiment, aspirin inhibited tyrosinase transcription after 3-day treatment (at 2-3 mM). However, TRP-1, TRP-2, and Mitf mRNA levels were not decreased with the same treatment (data not shown). This result is common to mefenamic acid and nimesulide treatment. Our results show that mefenamic acid and nimesulide inhibit tyrosinase gene transcription and subsequent protein expression without down-regulation of Mitf mRNA level. This result implies that these drugs inhibit transcription of tyrosinase and/or induce Mitf degradation. On the other hand, we could not confirm the inhibition of tyrosinase mRNA level by diclofenac treatment. This result indicate that diclofenac might induce tyrosinase protein degradation or suppress translation of tyrosinase mRNA.
In this report, we demonstrated the depigmentation effect of NSAIDs. NSAIDs inhibited cAMP-enhanced melanin production in B16F1 melanoma cells. The depigmenting mechanism of NSAIDs is not clear yet. Further investigate of the melanogenic mechanism of NSAIDs is extremely important, and we are currently conducting more studies. This study showed that NSAIDs are useful inhibitors of melanogenesis and they might be effective in hyperpigmentation disorders and whitening cosmetics.
